Stat Consult

Vemurafenib (Zelboraf)

This slideshow reviews vemurafenib (Zelboraf), indicated for the treatment of unresectable or metastatic melanoma with BRAF V600E mutation.

Ofatumumab (Arzerra)

This slideshow reviews ofatumumab (Arzerra), indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab (Campath).


This slideshow reviews vincristine, indicated for Hodgkin disease, Kaposi sarcoma, leukemia, neuroblastoma, non-Hodgkin lymphoma, rhabdomyosarcoma, and Wilms’ tumor.

Paclitaxel protein-bound particles (Abraxane)

This slideshow reviews paclitaxel protein-bound particles (Abraxane), indicated for metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer, and metastatic adenocarcinoma of the pancreas.

Pazopanib (Votrient)

This slideshow reviews pazopanib, indicated for the treatment of advanced renal cell carcinoma and advanced soft tissue sarcoma.

Azacitidine (Vidaza)

This slideshow reviews azacitidine (Vidaza), Indicated for the treatment of French-American-British (FAB) myelodysplastic syndrome subtypes.

Bendamustine (Treanda)

This slideshow examines bendamustine (Treanda), indicated for the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL).

Afatinib (Gilotrif)

This slideshow reviews afatinib (Gilotrif) for the treatment of non-small cell lung cancer (NSCLC).

Pertuxumab (Perjeta)

This slideshow reviews Pertuxumab (Perjeta) for the treatment of HER2-positive metastatic breast cancer in combination with trastuzumab (Herceptin) and docetaxel (Docefrez, Taxotere, generics) in patients who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.


This slideshow reviews Tamoxifen for the treatment of metastatic breast cancer in women and men

Next hm-slideshow in Slides